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for Women’s Health Research
Role of Environment and Sex Differences
in the Development of Autoimmune Diseases:
A Roundtable Meeting Report
Monica P. Mallampalli, PhD, MS,1 Erika Davies, PhD, MS,1 Debra Wood, PhD,1 Hillary Robertson,2
Federica Polato, PhD,1 and Christine L. Carter, PhD, MPH1
Abstract
Autoimmune diseases (ADs) impose substantial health and financial burdens in the United States and in many
parts of the world. Women are disproportionately affected by many of these disorders, which often contribute to
lifelong disabilities. While the number of patients with some ADs appears to be rising, the complexities of
conducting epidemiological studies prevent a thorough understanding of the prevalence and incidence of these
various conditions. Research on environmental influences of these illnesses is limited, although they are gen-
erally hypothesized to result from the interaction of environmental agents in genetically susceptible individuals.
Further, there is little known regarding the role of sex and gender in the environmentally influenced mechanisms
leading to the development of AD. To address these issues, particularly the roles of environment and sex and
gender in ADs and the factors that contribute to the rise in ADs, the Society for Women’s Health Research
convened an interdisciplinary roundtable of experts from academia, medicine, and government agencies to share
their expertise, address knowledge gaps in research, and propose future research recommendations.
Introduction
Autoimmune diseases (ADs) are a diverse group ofillnesses characterized by inflammatory responses
originating frommisdirected attacks of the immune system
on the body’s organ systems. More than 80 ADs have been
identified so far and the list continues to grow.1 ADs affect
*7%–10% of the U.S. population, of which *78% are
thought to be women.2,3,4 Collectively, ADs are the fifth
leading cause for death in women before age 65.5 These
diseases are a major public health problem due to their
chronic nature and associated comorbidities, which in-
crease the societal burden in terms of healthcare costs, loss
of work productivity, and reduced quality of life; however,
a complete understanding of the extent of the burden is
lacking.6
Our knowledge of AD etiologies is very limited; however,
several studies suggest that the environment acts on geneti-
cally susceptible individuals in causing most ADs.1,7 Genes
predisposing individuals to systemic lupus erythromatosis
(SLE) or lupus, rheumatoid arthritis (RA) and multiple scle-
rosis (MS) have been identified by genome wide association
studies.8 Low concordance rates in monozygotic twin studies
and the appearance of drug-induced lupus symptoms after
treatment with specific prescription medications followed
by the disappearance of symptoms upon withdrawal of the
medications indicate a role of the environment in ADs.1,9
Additional evidence for the role of the environment in the
development of ADs is reviewed in a series of recent publi-
cations originating from the 2012 National Institutes of En-
vironmental Health Sciences (NIEHS) Expert Panel
Workshop.1,9,10,11 While there are known genetic and envi-
ronmental components to ADs, more studies are needed to
understand the spectrum of genes and environmental agents
and the interactions between them to understand the etiology
of these diseases.
Recent epidemiological trends in the incidence rates of
some ADs have been attributed to environmental factors,
since large changes over a short period of time cannot be
explained by genetic contributions alone.12,13 Specifically, the
incidence of type 1 diabetes (T1D) has doubled every 20 years
in the United States and other populations.13 Similarly, the
1Scientific Programs, Society for Women’s Health Research, Washington, District of Columbia.
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incidence of SLE (female to male ratio of 9:1) has tripled in the
past four decades in the Rochester Epidemiology Project
(REP), Minnesota.12 RA rates (with 65%–75% female pre-
dominance) among women in the REP were on a sharp de-
cline over a period of four decades (1950s to mid-1990s).
Surprisingly, these rates have increased by 2.5% from 1995 to
2005.14 The reasons for this increase are unknown but have
been attributed to cumulative effects of environmental factors,
including diminished protective effects of oral contraceptives,
smoking, and probably vitamin D deficiency.14
Correlating a specific AD with a particular environmental
agent is complex and challenging. For example, the risk for a
specific AD (such as SLE) has been associated with more than
one environmental agent (silica, pesticides, cigarette smoking,
and Epstein Barr virus).15 On the other hand, several ADs
(including RA, SLE, Graves’ disease, and MS) have been as-
sociated with one particular environmental exposure (ciga-
rette smoking).1,7,15,16,17 Studies demonstrating such
correlations between the environmental exposure and ADs
are numerous; however, specific mechanisms underlying
such correlations have yet to be identified.
Sex and gender disparities are profound for ADs, as the
majority of ADs exhibit female bias, with women 2.7 times
more likely than men to acquire an AD.3,5,15,18 Strong female
predominance is exhibited by several ADs, including SLE,
Sjo¨rgren’s syndrome (SS), primary biliary cirrhosis, mixed
connective tissue diseases, and autoimmune thyroid diseases.
Some ADs, such as T1D, ulcerative colitis, and autoimmune
myocarditis, show weak or no female predominance,15 and
conditions such as Guillain Barre´ syndrome and psoriasis
show increased male bias.19,20 Although multiple hypotheses
have been proposed, the underlying cause and mechanisms
for sex biases are unknown.18 Some of the candidate factors
proposed to cause the sex bias include sex hormones, X
chromosome inactivation, X chromosome abnormalities, and
fetal microchimerism.21,18
ADs have substantial effects on women’s health and
quality of life. The age of onset for women to acquire an AD is
earlier than for men and in the case of SLE, 90% of cases occur
in women during 15–45 years of age.22 Women living with
ADs face many challenges, including uncertainty regarding
disease progression and prognosis and ability to function at
home and in society. Symptoms such as fatigue, depression,
sleep disturbance, pain, and sexual and cognitive dysfunction
are common in many ADs23,24,25 Sadly, maintaining a normal
lifestyle is very challenging for women with AD, especially
due to the lack of adequate social support and impact on
ability to work.
On October 5, 2012, the Society for Women’s Health Re-
search convened an interdisciplinary roundtable in Wa-
shington, DC of expert researchers (Table 1) (including
epidemiologists, basic scientists, clinicians, immunologists,
and toxicologists) to share their research interests, address
their thoughts on the role of environment on sex and gender
disparities, and discuss biological mechanisms underlying the
development of ADs. The participants were asked to com-
ment on mechanisms and factors contributing to the rise in
AD rates and provide consensus statements on future re-
search recommendations.
Environment, Sex/Gender, and Development of ADs
Dr. Frederick Miller provided an overview of how en-
vironment and gender (in this instance gender and sex were
used interchangeably) relate to autoimmunity and devel-
opment of ADs. Autoimmunity is defined by the presence
of autoreactive T and/or B cells, which cause the patho-
logical inflammation leading to the development of ADs.
Table 1. Society for Women’s Health Research Autoimmune Roundtable Participants List
and their Affiliations
Name Affiliation
S. Ansar Ahmed, DVM, PhD Professor and Head of the Department of Biomedical Sciences and Pathobiology
Virginia Tech University
Divaker Choubey, PhD Professor, Department of Environmental Health
University of Cincinnati College of Medicine
Glinda Cooper, PhD Senior Epidemiologist, National Center for Environmental Assessment
U.S. Environmental Protection Agency
DeLisa Fairweather, PhD Assistant Professor, Environmental Health Sciences
Johns Hopkins Bloomberg School of Public Health
Kathleen Gilbert, PhD Professor, Department of Microbiology and Immunology, University of Arkansas
for Medical Sciences
Frederick W. Miller, MD, PhD Acting Director, Clinical Research Program and Principal Investigator, National Institute
of Environmental Health Sciences, National Institutes of Health (NIH)
Marc Monestier, MD, PhD Director, Temple Autoimmunity Center
Professor, Microbiology and Immunology
Temple University
Prakash Nagarkatti, PhD Vice President for Research, Carolina Distinguished Professor Department of Pathology,
Microbiology, and Immunology
University of South Carolina School of Medicine
Christine G. Parks, PhD Research Scientist, Epidemiology
National Institute of Environmental Health Sciences, NIH
Bruce Richardson, MD, PhD Professor, Department of Internal Medicine
Chief of Rheumatology
Veteran’s Affairs Ann Arbor Healthcare System
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According to Dr. Miller, pathogenesis for ADs likely in-
volves chronic immune activation following environmental
exposures in genetically susceptible individuals. Although
precise mechanisms for the development of ADs are un-
known, several studies suggest that over time, the interac-
tion of the environment with genetic risk factors contributes
to the pathogenesis.26
Dr. Miller presented the following evidence for the role of
the environment in the pathogenesis of ADs: (1) strong tem-
poral associations with some exposures and disease onset
following exposure; (2) disease improvement after agent re-
moval; (3) disease reoccurrence when patients or animals are
re-exposed to the agent; (4) less than 50% disease concordance
in monozygotic twins; (5) correlation between seasonality in
birth rates and disease onset in some ADs; (6) geographic
clustering with onset of disease or disease prevalence; (7)
changes in disease incidence and prevalence over time; (8)
biological plausibility from in vitro and animal studies; and
finally, (9) epidemiological associations between particular
exposures and certain diseases.26
In 2012, Dr. Miller led a NIEHS expert panel workshop to
review 30 years of epidemiological literature to examine the
role of environment in the development of ADs. Using pre-
determined criteria, the panel reached a consensus about
several specific environmental agents with respect to their
role in the development of specific ADs, including (1) crys-
talline silica exposure contributes to the development of sev-
eral ADs (RA, SSc, SLE etc.); (2) solvent exposure contributes
to development of SSc; (3) smoking contributes to the devel-
opment of seropositive RA; and (4) an inverse relationship
exists between increased ultraviolet radiation exposure and
decreased risk for MS. Knowledge gaps identified by the pa-
nel were summarized by Dr. Miller and include a need for (1)
cost-effective, validated methods for assessing human expo-
sures; (2) more research on genotypes, phenotypes, and
multiple exposures; (3) a critical understanding of the effects
of the timing of exposures and dose responses; and (4) in-
creased resources to define associations of environmental
agents with disease. Unfortunately, carefully controlled and
adequately powered epidemiological studies are limited and
warrant additional study.1
According to Dr. Miller, genes that respond to environ-
mental exposures tend to be major risk factors for the devel-
opment of ADs. Dr. Miller discussed some supporting genetic
evidence, such as (1) increased prevalence in certain families
and ethnic groups, (2) gradients of disease concordance in
pedigrees, and (3) AD associations with many genes (such as
the HLA-DR gene haplotypes), some of which are shared
among multiple diseases.27 Dr. Miller pointed out that these
shared genetic risk factors for multiple ADs suggest a com-
mon pathogenic mechanism. For instance, epidemiological
studies have shown that the HLA-DR3 haplotypes are im-
portant for disease predisposition for SLE, MS, and T1D,
while DR9 haplotypes are shared in T1D and RA.27 Further,
Dr. Miller elaborated that sometimes certain genes and envi-
ronmental exposures induce protective effects. For example,
ingestion of l-tryptophan in some individuals led to the de-
velopment of eosinophilia–myalgia syndrome, whereas some
individuals remained unaffected following the ingestion.
Multivariate analyses showed the HLA DRB1*03 gene as a
risk factor in affected individuals and HLA DRB1*07 gene
appeared to be protective as it was found frequently in un-
affected individuals. Understanding protective genes, and
possibly protective environmental exposures, may one day
provide mechanistic clues for minimizing the development
of AD.28,26
In addition to environmental influences, studies have re-
vealed that possible mechanisms influencing female pre-
dominance in ADs may include both hormonal and genetic
effects. Sex hormones are primarily responsible for the
hormonal effects, with estrogen and prolactin tending to be
anti-inflammatory, and androgens tending towards pro-
inflammatory effects. Interestingly, prolactin leads to the
production of interferon (IFN)-c and high levels of IFN-c
have been associated with increased AD activity.29,30,31 The
use of hormone replacement therapies is thought to be as-
sociated with an increased risk of some ADs.32 Interestingly,
children exhibit female predominance in ADs as well, sug-
gesting involvement of other factors besides estrogen and
progesterone. Suggested genetic effects for female predom-
inance include epigenetics, incomplete or skewed X chro-
mosome inactivation in females, and the role of as-yet
unknown genes. Other possible effects attributed to female
predominance include microchimerism, preferential expo-
sures to environmental agents, and certain infections or
drugs.29 Evidence for female predominance in ADs comes
from the National Health and Nutrition Examination Survey
(1994–2004), a population-based study, which estimated the
prevalence of antinuclear antibodies (ANA; a clinical indi-
cator of autoimmunity) across age by sex in the United
States. As Dr. Miller explained, there was a female pre-
dominance of ANA at every age group in this study, with
female:male prevalence peaking for the 40–49 years age
group and decreasing at later ages. This result was true
across all ethnic and socioeconomic groups.33
In summary, Dr.Miller emphasized that ADs are on the rise
and possibly result from the interaction of environmental and
genetic factors over time. Both hormonal and nonhormonal
factors contribute to female predominance. Advances in
other complex diseases, such as novel technologies, statistical
approaches, and development of collaborating consortia and
focused resources, need to be applied to environmental
studies with the goal of interrupting AD associated patho-
genesis before the onset of illness.
Complexities and Challenges Associated
with Epidemiological Studies in ADs
Epidemiological data are typically presented as preva-
lence (proportion of cases for disease in a population at a
given time) and incidence (the number of new cases occur-
ring over a given time). Prevalence of ADs has risen in the
last few decades. Initially, Jacobson used literature reviews
of published studies (1965–1995) to estimate the total AD
prevalence as approximately 3.2%, across 24 selected ADs in
the United States.3 Using hospital registry data from 1977 to
2001, investigators in Denmark estimated the total preva-
lence across 31 diseases to be 5.2%.34 Dr. Glinda Cooper
discussed a more recent analysis using published results
from 1989 to 2008, which resulted in an estimated prevalence
of 7.6%–9.4% for 29 ADs.4 Dr. Cooper noted that changes in
diagnosis and test ordering could contribute to the changes
in incidence of some ADs over time, but these types of
diagnostic changes are unlikely explanations for the rising
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incidence seen in T1D. Improvements in the surveillance
methods and quality of epidemiologic researchmay improve
our understanding of disease burden and temporal trends in
the future.4
In order for the environmental exposures to cause a change
in the incidence of ADs, Dr. Cooper explained that the expo-
sure must be common throughout the population and should
have a relatively strong impact on risk of disease. For exam-
ple, prevalence of smoking men and women in the United
Kingdom decreased dramatically from 1950 to 1998.35 This
decrease could result in a decrease in diseases for which
smoking was a relatively strong risk factor, such as RA. Fur-
ther, Dr. Cooper mentioned that trends in environmental ex-
posures are affected by variations within populations. For
example, while occupational silica exposure is on the decline
in the United States, women are entering new work roles that
put them at risk for silica exposure.36 Thus, the population-
wide decrease in exposure does not reflect the gender-specific
increase in exposure. Research on multiple environmental
exposures is critical to our understanding of the incidence
trends. For example, use of multiple agents such as pesticides,
solvents, and phthalates increased dramatically post–World
War II and may have had combined effects on incidence and
prevalence rates of ADs. Dr. Cooper suggests that disease
associations can be observed even with small levels of expo-
sure. In conclusion, Dr. Cooper stressed the importance of
both collecting better incidence data for ADs and the need for
new methodologies to predict the effects of exposures on the
development of ADs.
Dr. Christine Parks addressed the role of sex, gender, and
the environment in systemic ADs and focused her discussion
on sex and gender-specific mechanisms related to farming/
pesticides. A modest association has been previously ob-
served, mostly in men, between farming and the risk for RA
and SLE.37,38,39 However, Dr. Parks explained a potential role
for pesticides as plausible triggers for these ADs. In addition
to pesticides, other immune-modifying exposures are present
in a farming environment, such as animals/infections, ultra-
violet rays, dusts, metals, diesel, and noise.40 In discussing the
role of gender in relation to farming and pesticides, Dr. Parks
expressed that women may not self-identify as farmers,
though they are often involved in farm work and are thus
exposed to potential triggers. Farmers and their families often
live where they work, so the occupational exposure of the
farm environment is actually shared among thosewho do and
do not self-identify as farmers. This makes it difficult to
identify associations between farming and gender since many
of the environmental exposures associated with the farming
are not adequately captured on surveys simply using the oc-
cupational title of ‘‘farmer.’’ Farmers and their spouses often
growup on farms andmay have had early exposures that lead
to the development of ADs, making causal relationships be-
tween current exposures and AD development difficult to
detect and once again making it challenging to establish as-
sociations between farming and gender.
Because many agricultural pesticides are also used in
residential settings (albeit at lower concentrations), Dr. Parks
looked at the effects of residential pesticides and RA/SLE
risk in Women’s Health Initiative (WHI) observational
study, where *76,000 post-menopausal women were con-
sidered at risk of RA/SLE.41 Dr. Parks and colleagues ex-
amined self-reported residential or workplace insecticide use
in relation to risk of RA/SLE (based on self-report and
concurrent use of antirheumatic drugs). The results indi-
cated that for women without prior farm experience, per-
sonal exposures to insecticides were associated with
increased risks of SLE and RA. The smaller subgroup of
women who lived on farms had an even higher risk for SLE
and RA. Since it was not possible to study early life expo-
sures in the WHI, Dr. Parks evaluated the Sister Study co-
hort, which included more than 50,000 women aged 35–74.
Dr. Parks found that RA risk was associated with more fre-
quent residential pesticide application and personal use of
insecticides in childhood, in addition to markers of low so-
cioeconomic factors such as household education, young
maternal age, and paternal smoking, emphasizing the im-
portance of studying early life exposures.42
Dr. Parks addressed the difficulties in assessing early life
exposures, difficulty with extrapolating findings from animal
studies to humans, and determining the in utero and child-
hood exposures in epidemiological studies. For these reasons,
Dr. Parks proposes designing better questionnaires to assess
early exposures, along with studies to determine biologic ef-
fects associated with the questionnaires.
In summary, Dr. Parks remarked that women might have
unique exposures to environmental factors requiring further
research into gender-specific exposure assessment methods
and determination of female susceptibility. If women are
more susceptible, then an understanding of the factors that set
the stage for sex-specific susceptibility is needed.
Biological Mechanisms in the Development of ADs
Sex differences, sex hormones, and immune
regulation in ADs
InDr. DeLisa Fairweather’s opinion, unlike the cancer field,
the AD field is splintered and would benefit from the
grouping of ADs based on common themes such as pathol-
ogy, age, and sex to help understand AD etiology. For ex-
ample, pathology needs to be evaluated in a context
dependent manner, as it is important to consider the organ
involved in a specific AD and also the type of immune re-
sponse that is being generated. Dr. Fairweather discussed a
review from 2008, in which she grouped ADs based on age
and sex and clearly showed sex differences in the pathological
mechanisms of ADs for acute and chronic pathologies.2 Re-
gardless of sex, acute immune pathology involves inflam-
matory immune responses, while chronic pathology is
characterized by fibrosis, the formation of scar tissue as a re-
sult of inflammation or repair from injury. Interestingly,
grouping ADs based onmale or female predominance reveals
that the types of inflammatory immune responses driving
acute versus chronic pathology differ. Male-predominant
ADs that manifest before age 50 are characterized by a mixed
Th1/Th17 immune response resulting in acute pathology
through cell-mediated acute inflammation and presence of
autoantibodies (autoAbs). In contrast, acute pathologies of
female predominant ADs are driven by Th2, antibody-medi-
ated responses. Both male and female predominant AD pa-
thologies progress to a chronic condition in people around age
50. Regardless of the T helper (Th)1/Th17 or Th2 acute pa-
thology, the chronic pathology is characterized by chronic
fibrosis.2 As this analysis shows, evaluating epidemiological
data based on the grouping of ADs and subsequent analysis
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by sex, pathology, and age can provide information regarding
disease mechanisms that would be otherwise impossible, due
to low incidence rates for specific diseases.
In addition to the Th1/Th2 bias for men and women re-
spectively, Dr. Fairweather discussed an important compo-
nent of the innate immune system, which may play a role in
AD pathology: mast cells. Mast cells are located throughout
the body, interface directly with sex hormones and other
immune factors, and are known to drive both acute and
chronic immune responses through Th1-, Th2-, and Th17-
mediated mechanisms. Further, mast cells activate the in-
flammasomes in response to ‘‘danger signals’’ from damaged
‘‘self’’. These cytoplasmic multiprotein complexes are found
in innate immune cells and have been implicated in AD pa-
thology. However, our knowledge of mast cells and the in-
flammasome responses to environmental factors is poorly
understood andmore research is required to understand their
possible role in AD pathogenesis. In conclusion, Dr. Fair-
weather emphasized the need for future research studies to
analyze data by sex, examine exposures for ‘‘groups’’ of ADs,
examine sex differences in antibody/autoAb responses in
patients and animal models, and study inflammasome-driven
responses to pertinent environmental agents.
Dr. Divaker Choubey further discussed the role of the
immune system in AD pathogenesis, focusing on the role of
IFNs and inflammasomes in environmentally induced in-
flammation. IFNs are a family of cytokines that play a role in
inflammation and bind to cell surface receptors ultimately
leading to activation of IFN-inducible genes and translation
of IFN-inducible proteins such as the p200 protein family.
Upon sensing cytoplasmic DNA, these proteins assemble
the inflammasomes. Interestingly, female predominant ADs
are associated with elevated levels of IFN messenger RNAs
(mRNAs) (‘‘IFN signature’’), which encode the p200 pro-
teins.31 Simultaneously, autoAb–DNA complexes (clinical
hallmarks of ADs) are taken up by the macrophages and
other innate immune cells, leading to DNA localization in
the cytoplasm. Detection of this cytoplasmic DNA by certain
p200 proteins results in the activation of inflammasomes,
leading to increased secretion of proinflammatory cytokines
such as interleukin (IL)-1b and IL-18.31, 43 The inflamma-
somes may provide a point of intersection for sex factors—
such as the IFN signatures in women—and environmental
exposures.
Dr. Choubey discussed a new congenic mouse model
(B6.Nba2) that develops lupus-like disease and exhibits both
sex bias and the IFN signature associated with lupus. These
mice have increased levels of autoAbs against nuclear anti-
gens and double stranded DNA; yet, they do not develop
kidney disease.44 Dr. Choubey discussed a region of DNA, the
Nba2 interval that contains three candidate lupus suscepti-
bility genes, including the ifi200, encoding the p200 family
proteins. Interestingly, interactions among the three lupus
susceptibility genes are required to develop autoAbs.45 Recent
discoveries from this murine model of autoimmunity include
(1) sex hormones regulate the expression of p200 family
proteins,46,47,48 (2) IFN signaling regulates the expression of
estrogen receptor a, and (3) polymorphisms in interferon-
regulated factor 5 (IRF5) predisposes individuals to increased
production of IFNs with estrogen further up-regulating the
IRF5 expression49,50 In conclusion, Dr. Choubey stressed the
need for further studies to assess the role of p200 family
proteins in autoimmunity induced by both estrogen and en-
vironmental exposures.
Epigenetic alterations and microRNA regulation in ADs
Epigenetics involve alterations in gene expression through
mechanisms other than DNA sequence modification. Com-
mon epigenetic mechanisms are DNA methylation, histone
modifications, and microRNA (miRNA) regulation. The role
of epigenetics in the development of ADs has been a subject of
recent interest and investigation. SLE-inducing drugs, such as
procainamide and hydralazine, cause lupus-like autoimmu-
nity in mouse models through T-cell DNA demethylation.51
Similar epigenetic changes have been identified in some SLE
patients, sparking interest in a possible role for epigenetics in
the development of SLE.52 Dr. Bruce Richardson addressed
how epigenetic alterations in immune cells may lead to AD
etiology. He explained that environmental agents such as
drugs and ultraviolet light induce epigenetic changes in the
CD4 + T-cell genome causing inhibition of DNA methylation
of T-cell DNA.51 This leads to the overexpression of number of
genes causing the T cells to become autoreactive, cytotoxic,
and pro-inflammatory. Dr. Richardson showed striking data
that in women with SLE, the promoter of the immune asso-
ciated gene, CD40L, is demethylated, resulting in over-
expression of CD40L.53 Interestingly, this phenomenon is not
seen in men with lupus. Since CD40L is found on the X
chromosome, this finding creates an interesting parallel with
the idea that partial demethylation of the X chromosome, and
consequent overexpression of some X chromosome genes,
may contribute to the sex bias observed for several ADs.54 Dr.
Richardson proposed that since having two X chromosomes is
the strongest predisposing factor for the development of lu-
pus, with 90% of affected individuals being women, men
suffering from lupus must require a greater degree of T-cell
DNA demethylation, a greater total genetic risk, or both, to
develop a lupus flare of equal severity as those experienced by
women.
Dr. Ansar Ahmed discussed the role of another epigenetic
mechanism, miRNAs, in AD development. MicroRNAs or
miRNAs are small, evolutionarily conserved, noncoding
RNAs that interact with mRNAs leading to mRNA cleavage
and degradation or direct inhibition of translation. According
to Dr. Ahmed, dysregulation of a subset of miRNAs involved
in both innate and adaptive immune functions contributes to
autoimmunity in RA, lupus, MS, systemic scleroderma (SSc),
and Sjo¨rgen syndrome, each with a unique pattern of miRNA
dysregulation.55–59 For example, in SLE, genetic, hormonal,
and environmental factors dysregulate miRNAs, resulting in
changes in gene expression that culminate in the breakdown
of self-tolerance, induction of inflammatory cytokines, pro-
duction of autoAbs, aberrant DNA hypomethylation, and
dysregulated T regulatory cells.57 Dr. Ahmed discovered a
common set of dysregulated miRNAs (miRNA182-96-183
cluster, miR31, and miR155) in three different murine lupus
models on differing genetic backgrounds (MRL-lpr, B6-lpr,
and NZB/WF1).60 Interestingly, sex differences were evident
in the NZB/WF1 mice, where the expression of the miRNA
182-96 cluster correlated with the onset of lupus in female
mice. Dr. Ahmed has also shown that a particular miRNA
(miRNA146a) is selectively regulated by estrogen in immune
cells, suggesting a role for miRNAs in estrogen-mediated
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immune regulation.61 According to Dr. Ahmed, miRNAs
may help to understand AD pathogenesis and also have the
potential to serve as biomarkers for diagnosis.
Dr. Prakash Nagarkatti further explained that miRNAs
expression in immune cells is altered following exposure
to environmental contaminants such as 2,3,7,8-tetra-
chlorodibenzo-p-dioxin (TCDD). Dr. Nagarkatti’s laboratory
performed miRNA arrays in fetal thymocytes folloowing
prenatal expsure to TCDD. They screened 608 mouse miR-
NAs and found that 106 miRNAs were altered significantly in
fetal thymocytes post-TCDD exposure when compared with
vehicle controls.62 Furthermore, several of the miRNAs that
were downregulated contained highly complementary se-
quence to the 3¢-untranslated region of several genes includ-
ing AhR, CYP1A1, Fas, and FasL. Because Fas and Fas ligand
are involved in the regulation of apoptosis and AD, these data
suggested that prenatal exposure to TCDD may alter the
immune response and increase the susceptibility to AD. These
data were consistent with their earlier studies using an HY-T-
cell receptor transgenic mouse model to study the develop-
ment of T cells, in which it was noted that TCDD altered the
negative and positive selection of T cells in the thymus.63 In-
asmuch as these processes play a critical role in the regulation
of AD, the data suggested that prenatal exposure to TCDD
may increase susceptibility to AD. This was also corroborated
by demonstrating that TCDD exposure may enhance immune
response to self-antigens.63
Epigenetic modification by CpG methylation at specific
sites in the promoters of various genes, expressed in T cells, is
known to regulate T cell differentiation into various subsets.
Both Foxp3 and IL-17 genes possess CpG islands in their
promoter regions. Dr. Nagarkatti’s laboratory examined the
methylation status of CpG islands present in Foxp3 and IL-17
promoters following aryl hydrocarbon receptor (AhR) acti-
vation. Activation of T cells from AhR+/+ but not AhR–/–
mice, in the presence of TCDD, promoted increased differ-
entiation of regualtory T cells (Tregs) while inhibiting Th17
cells. This correlated with the findings that TCDD caused
decreasedmethylation of CpG islands of Foxp3 and enhanced
methylation of IL-17 promoters.64 In contrast, another AhR
ligand, a specific photoproduct of tryptophan, 6-for-
mylindolo[3,2-b]carbazole (FICZ) was shown to have the ex-
act opposite effects. Thus, FICZ increased the differentiation
of Th17 cells while inhibiting Tregs. While both TCDD and
Table 2. Proposed Research Recommendations in Autoimmune Disease Research from the SWHR
Autoimmune Roundtable
Analyze epidemiological data to:
1. Estimate disease burden from a woman’s health perspective;
2. Group autoimmune diseases by pathology, sex, and race in order to evaluate relationship among them;
3. Determine role of environmental agents in influencing autoimmune disease incidence trends in adults;
4. Detect and measure early life/emerging exposures in males and females;
5. Identify disease phenotypes and risk factors by sex;
6. Determine role of emerging technologies in altering immune responses.
Examine biological mechanisms to:
1. Understand role of different periods in lifespan (from in utero to menopause and beyond) and autoimmune disease;
2. Determine relationship between immune dysregulation and autoimmunity, including sex differences if any;
3. Determine role of biomarkers to predict disease onset and progression from autoimmunity to autoimmune diseases;
4. Study epigenetics and epigenetic modulators in autoimmunity;
5. Understand role of lung and immune responses within the lung in different autoimmune diseases;
6. Understand role of microbiome in autoimmune disease;
7. Determine role of obesity in response to environmental factors;
8. Link endogenous estrogen variability to disease manifestation;
9. Elucidate sex differences in
a. Phenotypic expression and disease severity of particular autoimmune diseases;
b. Adaptive and innate immune sentinel cells (that interact with environmental factors);
c. Autoantibody titers and more general immune responses;
d. Inflammasome biology;
e. Regulatory mechanistic pathways that prevent autoimmune diseases;
f. Obesity and fat deposition (and how that affects autoimmune disease development and progression);
g. Animal models of toxicity;
h. Multiple exposures and their interactions;
i. Both genetic and environmental protective factors.
Establish resources for:
1. A national-based registry and repository for all autoimmune diseases;
2. Interdisciplinary research group with various stakeholders for cost-effective collaboration;
3. Curriculum for allied health professionals;
4. Appropriate NIH study section and special emphasis panel on sex differences research;
5. Autoimmune disease parameters within the National Toxicity Program and examine autoimmune disease outcomes
by sex.
Roundtable participants were asked to provide key recommendations based on existing knowledge gaps in the autoimmune disease field
to facilitate progress in the autoimmune disease research. Consensus statements provided by the roundtable participants have been
summarized into three categories.
NIH, National Institutes of Health.
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FICZ are potent ligands of AhR, why these ligands behave
differently remains an enigma. Preliminary studies indicated
that this may result from differential induction of miRNAs. If
environmental or dietary AhR ligands were to increase Th17
induction through epigenetic regulation, they could trigger or
enhance certain inflammatory and ADs. Clearly, additional
studies are necessary to investigate the effect of AhR ligands
on epigenetic regulation of genes involved Treg and Th17 cell
differentiation as well as miRNAs because such regulation
may play a key role in the pathogenesis of a large number
of ADs.
Chemical exposures
Trichloroethylene (TCE) is an industrial organic solvent
used in the production of hydrofluorocarbons and is a major
environmental pollutant. Epidemiological studies have linked
TCE to increased incidences of ADs such as SLE, SSc, and
autoimmune hepatitis (AH). Dr. Kathleen Gilbert observed a
direct effect of TCE in lupus-prone mice following chronic
exposure to TCE, though surprisingly, accelerated AH rather
than SLE was observed in these mice. AH is characterized by
an infiltration of T cells in bothmice and humans. The disease,
although rare, is foundmore often in women (70% cases) than
in men.65 In the mouse model, a 4-week TCE exposure in-
creased CD4+ T cell IFN-c expression and synthesis.65 Dr.
Gilbert hypothesized that TCE exposure leads to global gene
methylation, resulting in the observed increase in IFN-c. Her
current working hypothesis for sex bias is that TCE metabo-
lism by the liver leads to gender-associated alterations in the
methylation pathways in CD4+ T cells, eventually causing
AH.
Dr. Marc Monestier discussed a connection between mer-
cury, autoimmunity, and gender. Currently, there is insuffi-
cient evidence to show that exposure to metals, including
mercury, leads to the development of any particular AD.1
High exposure to mercury induces changes in the central
nervous system and the cardiovascular system, and toxic ef-
fects ofmercury have been described following exposure from
seafood, skin lightening creams, and gold mining.66–69 Mer-
cury-exposed goldminers in Brazil were found to have higher
levels of ANA antibodies compared with non-mercury min-
ers, suggesting that mercury exposure can lead to antibody
responses that are characteristic of autoimmunity.70 Further,
Dr. Monestier described divergent effects between female and
male mice offspring following postnatal exposure of the mo-
ther tomercury, with female offspring exhibiting a decrease in
regulatory T cells. He further stated that the biodistribution,
toxiocokinetics, andmercury accumulation differ between the
sexes, though this research area remains largely unexplored.
Research Recommendations and Conclusion
The roundtable participants identified future research rec-
ommendations, based on existing knowledge gaps in the field
of ADs (Table 2). While progress has been made in the un-
derstanding of AD etiology, it has been slow and primarily
limited to only few ADs. Further, identification of environ-
mental agents and studies on their interaction with genetic
components in the development of ADs may help prevent the
rise in AD rates. Several challenges still exist in AD research,
including (1) sub-optimal coordination among researchers,
agencies, and nations; (2) inadequate validated exposure
biomarkers/assessment tools and training in environmental
studies; and (3) limited population-based prevalence, inci-
dence, and demographic information, including lack of stan-
dardized AD phenotype databases and registries. A clear
knowledge of the basicmechanisms underlying these diseases
is much needed to understand the role of environment and
sex bias in ADs.
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